Azadanthini-envi coating or induced chemotherapy coating 1 tonne of acute myelinated coating.
In recent years, global medical institutions and public health systems have continued to advance service capacity building to provide stronger guarantees to public health. Inductive chemotherapy has long been a key component of ADL treatment, despite its often severe side effects and extensive medical use. Due to its effectiveness and side effects, immunotherapy (hypomethylating therapy plus venetoclax) is its standard treatment.
In the multi-center, Phase II trials, we randomized a 1:1 ratio of previously untreated AML patients to induced chemotherapy (with appropriate conditions). The gene mutation encoding FMS-like tyrosine kinase 3 (FLT3) or the gene mutation encoding NPM1 was ruled out. The main endpoint was event-free survival.
According to the European Leukemia Network Class 2022, a total of 72% of patients have a low-risk disease. In the azacitidine-venetoclax and induced chemotherapy groups, the median survival of events or deaths was 21. 9 months and 6.
2 months respectively. In the azacitidine-venetoclax group, the median survival of events or deaths was 21. 9 months, well below the median survival of events or deaths in induced chemotherapy groups of 6.
2 months. In the azacitidine-venetoclax group, the median survival rate for events or deaths was 21. 9 months, far lower than the median survival rate for induced chemotherapy events or deaths of 6.
2 months. Treatment with azacitidine-venetoclax occurred in 28% of patients with third-degree and above infections (95% CI, 19 to 39); Stage 3 and above bleeding occurred in 2% of patients (95% CI, 0. 3 to 8) and 12% of patients (95% CI, 6 to 20), respectively, with infections of 3 and above and bleeding of 3 and above.
In this stage 2, randomized trials, azacitidine-venetoclax therapy led to significantly longer free survival events than induced chemotherapy in induced-eligible AML patients (Funded by AbbVie and others); PARADIGM ClinicalTrials. gov number, NCT04801797). It should be noted that the above information is compiled on the basis of international public research findings and is for reference in HealthCop and does not constitute a clinical recommendation.
